Global Immunity Support Ingredients Market Strategic Research Report
By Type: Vitamin C, Vitamin E, Other Vitamins, Beta Glucans, Carotenoids, Phytosterols, Omega-3 Fatty Acids
By Application: Nutrition Supplements, Foods & Beverages, Pharmaceuticals, Feeds, Pet Foods, Personal Care Products, Other
Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America
Key Players: DSM (NL), BASF SE (DE), Archer Daniels Midland Company (US), International Flavors & Fragrances Inc. (US), Kerry Group plc (IE), Novonesis (DK), FrieslandCampina Ingredients (NL), Fonterra Co-operative Group Limited (NZ), Arla Foods Ingredients Group P/S (DK), BENEO GmbH (DE), Angel Yeast Co., Ltd. (CN), Lesaffre (FR), Balchem Corporation (US), Glanbia plc (IE), MartinBauer Group (US), Indena S.p.A. (IT), Sabinsa Corporation (US), Euromed S.A. (ES), Probi AB (SE), BioGaia AB (SE), Morinaga Milk Industry Co., Ltd. (JP), Lallemand Inc. (CA), Zhejiang NHU Co., Ltd. (CN), CSPC Pharmaceutical Group Limited (CN), Northeast Pharmaceutical Group Co., Ltd. (CN), Zhejiang Medicine Co., Ltd. (CN), Roquette Frères (FR), Tate & Lyle PLC (GB), Hunan Green-Spring Biotechnology Co., Ltd. (CN), Croda International Plc (GB), EPAX AS (NO), Bluestar Adisseo Company (CN), Raisio plc (FI)
개요
Scope of the Report
The global Immunity Support Ingredients market size is predicted to grow from US$ 18,400 million in 2025 to US$ 26,220 million in 2032; it is expected to grow at a CAGR of 5.3% from 2026 to 2032.
Immune-supporting ingredients are functional nutritional raw materials used in dietary supplements, functional foods and beverages, gummies, tablets, capsules, powders, and products for infant, geriatric, sports, and specialized nutrition. They serve to support normal immune system function, replenish key micronutrients, improve gut microbiota, provide bioactive plant compounds, and enhance daily health management. Key examples include Vitamin C, Vitamin D, zinc, selenium, probiotics, postbiotics, prebiotics, dietary fiber, yeast beta-glucan, lactoferrin, colostrum powder, elderberry extract, echinacea extract, curcumin, and nutritional premixes. In 2025, the global immune-supporting ingredient industry is projected to have an average capacity utilization rate of approximately 76.8% and a gross profit margin of about 31.5%. Upstream enterprises primarily engage in vitamin synthesis, mineral salt production, dairy processing, probiotic and yeast fermentation, plant cultivation and extraction, enzyme production, encapsulation and packaging materials, and testing services. Downstream sectors mainly include dietary supplements, functional foods and beverages, dairy products, nutrition for infants and the elderly, sports nutrition, gummies, dual-use medicinal and food products, and contract manufacturing. The product cost structure is approximately as follows: vitamin and mineral raw materials (24%); probiotic strains and fermentation costs (15%); plant extracts and dairy-derived bioactive ingredients (18%); yeast beta-glucan, prebiotics, and dietary fiber (13%); labor and manufacturing overhead (8%); testing, certification, and regulatory compliance (6%); energy and environmental protection (5%); packaging, warehousing, and logistics (5%); and R&D, application support, and administrative expenses (6%). The list of required ingredients includes Vitamin C, Vitamin D, zinc, selenium, vitamin-mineral premixes, probiotic powder, postbiotics, inulin, fructooligosaccharides (FOS), yeast beta-glucan, lactoferrin, colostrum powder, elderberry extract, echinacea extract, and raw materials for immune-support gummy formulations. Downstream clients include brands of dietary supplements, functional beverages, functional foods, nutritional gummies, infant and child nutrition products, senior nutrition products, sports nutrition, and health foods, as well as contract manufacturers and premix formulators. Business opportunities are driven by policies promoting healthy aging, child nutrition, the standardization of health foods, sugar reduction, and the growing demand for daily health management. Technological innovation is driven by advancements in strain screening, postbiotic stabilization, lactoferrin isolation and purification, standardization of plant extracts, microencapsulation, synergistic ingredient combinations, and dosage form optimization. Meanwhile, shifting consumer demands are driving product upgrades—moving from simple vitamin supplementation toward scientifically formulated, multi-ingredient products targeting gut health and immunity (for children and seniors) and formats such as ready-to-eat gummies and ready-to-drink beverages.
The immune support ingredient sector is a growth-oriented functional nutrition market built upon a mature foundation; overall demand has shifted from the short-term, emergency-driven consumption seen during the pandemic toward consumption patterns characterized by daily use, specific usage scenarios, and evidence-based efficacy. Vitamins C and D, zinc, and selenium remain the staples of basic demand, featuring transparent pricing, mature supply chains, and competition driven primarily by cost and scale. Conversely, ingredients such as probiotics, postbiotics, lactoferrin, yeast beta-glucan, elderberry, echinacea, inulin, and complex premixes represent higher value-added segments, where customers prioritize scientific evidence, active ingredient stability, taste, dosage form suitability, and regulatory compliance. Over the next six to eight years, the immune health concept will move beyond simple "immune-boosting" claims to drive growth; instead, it will integrate with areas such as gut health, pediatric growth, elderly nutrition, sports recovery, sleep and stress management, and low-sugar functional foods to meet multifaceted, scenario-based demands. While North American and European markets place greater emphasis on clinical evidence, branded ingredients, and compliant health claims, China and India hold distinct advantages in the supply of vitamins, botanical extracts, yeast-based ingredients, and cost-competitive raw materials; meanwhile, Japan, South Korea, and Taiwan excel in probiotics and fermented nutritional products. Future industry growth is expected to remain steady, with leading enterprises enhancing their bargaining power through diversified product portfolios, global customer certifications, ingredient traceability, formulation services, and regulatory support. Small and medium-sized enterprises, meanwhile, will need to seek differentiation opportunities in specialized botanical extracts, patented strains, customized premixes, and regional supply chain capabilities.
This report presents a comprehensive overview of the global Immunity Support Ingredients market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.
Segment by Type
- Vitamin C
- Vitamin E
- Other Vitamins
- Beta Glucans
- Carotenoids
- Phytosterols
- Omega-3 Fatty Acids
Segment by Dosage Form
- Liquid
- Powder
- Capsule/Tablet
Segment by Purity
- ≥95%
- ≥98%
- ≥99%
- Other
Segment by Application
- Nutrition Supplements
- Foods & Beverages
- Pharmaceuticals
- Feeds
- Pet Foods
- Personal Care Products
- Other
Who Can Use This Report?
This report is written for decision-makers who need a clear, data-backed view of the global Immunity Support Ingredients market:
- Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
- Distributors, channel partners and end users in Nutrition Supplements, Foods & Beverages, Pharmaceuticals evaluating demand and sourcing options
- Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
- Government agencies, industry associations and research institutions tracking industry developments and policy impact
Market snapshot
Global Immunity Support Ingredients Market Strategic Research Report snapshot, 2025–2032
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.Segments covered in this report
Table of contents
01Executive Summary
02Industry Overview & Forecast
- 2.1.1 Market Definition and Scope
- 2.1.2 Market Size and Growth Forecast
- 2.1.3 Volume Analysis
- 2.1.4 Segment Outlook by Type
- 2.1.5 Segment Outlook by Application
- 2.1.6 Regional Outlook
- 2.1.7 Structural Developments Shaping the Forecast
- 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
- 3.1 Market Segmentation by Type
- 3.1.1 Market by Type Overview
- 3.1.2 Vitamin C
- 3.1.3 Vitamin E
- 3.1.4 Other Vitamins
- 3.1.5 Beta Glucans
- 3.1.6 Carotenoids
- 3.1.7 Phytosterols
- 3.1.8 Omega-3 Fatty Acids
- 3.1.9 Volume Analysis
04Market Segmentation by Application
- 4.1 Market Segmentation by Application
- 4.1.1 Market by Application Overview
- 4.1.2 Nutrition Supplements
- 4.1.3 Foods & Beverages
- 4.1.4 Pharmaceuticals
- 4.1.5 Feeds
- 4.1.6 Pet Foods
- 4.1.7 Personal Care Products
- 4.1.8 Other
- 4.1.9 Volume Analysis
05Regional Market Forecast
- Asia Pacific
- North America
- Europe
- Middle East & Africa
- Latin America
06Country-Level Market Forecast
- 6.1 Asia Pacific
- 6.1.1 China
- 6.1.2 Japan
- 6.1.3 Korea
- 6.1.4 Southeast Asia
- 6.1.5 India
- 6.1.6 Australia
- 6.1.7 Rest of Asia Pacific
- 6.2 North America
- 6.2.1 United States
- 6.2.2 Canada
- 6.2.3 Mexico
- 6.2.4 Rest of North America
- 6.3 Europe
- 6.3.1 Germany
- 6.3.2 France
- 6.3.3 UK
- 6.3.4 Italy
- 6.3.5 Russia
- 6.3.6 Rest of Europe
- 6.4 Middle East & Africa
- 6.4.1 Egypt
- 6.4.2 South Africa
- 6.4.3 Israel
- 6.4.4 Turkey
- 6.4.5 GCC Countries
- 6.4.6 Rest of Middle East & Africa
- 6.5 Latin America
- 6.5.1 Brazil
- 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
- 7.1 Growth Drivers & Inhibitors
- 7.1.1 Section Overview
- 7.1.2 Growth Drivers
- 7.1.3 Growth Inhibitors
- 7.1.4 Driver and Inhibitor Impact Assessment
- 7.1.5 Analyst Perspective
08Key Company Profiles
- 8.1 DSM (NL)
- 8.1.1 Company Overview
- 8.1.2 Key Products & Segments
- 8.1.3 Financial Performance (2023–2025)
- 8.1.4 Business Strategy
- 8.1.5 SWOT Analysis
- 8.1.6 Strategic Implications (2026–2032)
- 8.2 BASF SE (DE)
- 8.2.1 Company Overview
- 8.2.2 Key Products & Segments
- 8.2.3 Financial Performance (2023–2025)
- 8.2.4 Business Strategy
- 8.2.5 SWOT Analysis
- 8.2.6 Strategic Implications (2026–2032)
- 8.3 Archer Daniels Midland Company (US)
- 8.3.1 Company Overview
- 8.3.2 Key Products & Segments
- 8.3.3 Financial Performance (2023–2025)
- 8.3.4 Business Strategy
- 8.3.5 SWOT Analysis
- 8.3.6 Strategic Implications (2026–2032)
- 8.4 International Flavors & Fragrances Inc. (US)
- 8.4.1 Company Overview
- 8.4.2 Key Products & Segments
- 8.4.3 Financial Performance (2023–2025)
- 8.4.4 Business Strategy
- 8.4.5 SWOT Analysis
- 8.4.6 Strategic Implications (2026–2032)
- 8.5 Kerry Group plc (IE)
- 8.5.1 Company Overview
- 8.5.2 Key Products & Segments
- 8.5.3 Financial Performance (2023–2025)
- 8.5.4 Business Strategy
- 8.5.5 SWOT Analysis
- 8.5.6 Strategic Implications (2026–2032)
- 8.6 Novonesis (DK)
- 8.6.1 Company Overview
- 8.6.2 Key Products & Segments
- 8.6.3 Financial Performance (2023–2025)
- 8.6.4 Business Strategy
- 8.6.5 SWOT Analysis
- 8.6.6 Strategic Implications (2026–2032)
- 8.7 FrieslandCampina Ingredients (NL)
- 8.7.1 Company Overview
- 8.7.2 Key Products & Segments
- 8.7.3 Financial Performance (2023–2025)
- 8.7.4 Business Strategy
- 8.7.5 SWOT Analysis
- 8.7.6 Strategic Implications (2026–2032)
- 8.8 Fonterra Co-operative Group Limited (NZ)
- 8.8.1 Company Overview
- 8.8.2 Key Products & Segments
- 8.8.3 Financial Performance (2023–2025)
- 8.8.4 Business Strategy
- 8.8.5 SWOT Analysis
- 8.8.6 Strategic Implications (2026–2032)
- 8.9 Arla Foods Ingredients Group P/S (DK)
- 8.9.1 Company Overview
- 8.9.2 Key Products & Segments
- 8.9.3 Financial Performance (2023–2025)
- 8.9.4 Business Strategy
- 8.9.5 SWOT Analysis
- 8.9.6 Strategic Implications (2026–2032)
- 8.10 BENEO GmbH (DE)
- 8.10.1 Company Overview
- 8.10.2 Key Products & Segments
- 8.10.3 Financial Performance (2023–2025)
- 8.10.4 Business Strategy
- 8.10.5 SWOT Analysis
- 8.10.6 Strategic Implications (2026–2032)
- 8.11 Angel Yeast Co., Ltd. (CN)
- 8.11.1 Company Overview
- 8.11.2 Key Products & Segments
- 8.11.3 Financial Performance (2023–2025)
- 8.11.4 Business Strategy
- 8.11.5 SWOT Analysis
- 8.11.6 Strategic Implications (2026–2032)
- 8.12 Lesaffre (FR)
- 8.12.1 Company Overview
- 8.12.2 Key Products & Segments
- 8.12.3 Financial Performance (2023–2025)
- 8.12.4 Business Strategy
- 8.12.5 SWOT Analysis
- 8.12.6 Strategic Implications (2026–2032)
- 8.13 Balchem Corporation (US)
- 8.13.1 Company Overview
- 8.13.2 Key Products & Segments
- 8.13.3 Financial Performance (2023–2025)
- 8.13.4 Business Strategy
- 8.13.5 SWOT Analysis
- 8.13.6 Strategic Implications (2026–2032)
- 8.14 Glanbia plc (IE)
- 8.14.1 Company Overview
- 8.14.2 Key Products & Segments
- 8.14.3 Financial Performance (2023–2025)
- 8.14.4 Business Strategy
- 8.14.5 SWOT Analysis
- 8.14.6 Strategic Implications (2026–2032)
- 8.15 MartinBauer Group (US)
- 8.15.1 Company Overview
- 8.15.2 Key Products & Segments
- 8.15.3 Financial Performance (2023–2025)
- 8.15.4 Business Strategy
- 8.15.5 SWOT Analysis
- 8.15.6 Strategic Implications (2026–2032)
- 8.16 Indena S.p.A. (IT)
- 8.16.1 Company Overview
- 8.16.2 Key Products & Segments
- 8.16.3 Financial Performance (2023–2025)
- 8.16.4 Business Strategy
- 8.16.5 SWOT Analysis
- 8.16.6 Strategic Implications (2026–2032)
- 8.17 Sabinsa Corporation (US)
- 8.17.1 Company Overview
- 8.17.2 Key Products & Segments
- 8.17.3 Financial Performance (2023–2025)
- 8.17.4 Business Strategy
- 8.17.5 SWOT Analysis
- 8.17.6 Strategic Implications (2026–2032)
- 8.18 Euromed S.A. (ES)
- 8.18.1 Company Overview
- 8.18.2 Key Products & Segments
- 8.18.3 Financial Performance (2023–2025)
- 8.18.4 Business Strategy
- 8.18.5 SWOT Analysis
- 8.18.6 Strategic Implications (2026–2032)
- 8.19 Probi AB (SE)
- 8.19.1 Company Overview
- 8.19.2 Key Products & Segments
- 8.19.3 Financial Performance (2023–2025)
- 8.19.4 Business Strategy
- 8.19.5 SWOT Analysis
- 8.19.6 Strategic Implications (2026–2032)
- 8.20 BioGaia AB (SE)
- 8.20.1 Company Overview
- 8.20.2 Key Products & Segments
- 8.20.3 Financial Performance (2023–2025)
- 8.20.4 Business Strategy
- 8.20.5 SWOT Analysis
- 8.20.6 Strategic Implications (2026–2032)
- 8.21 Morinaga Milk Industry Co., Ltd. (JP)
- 8.21.1 Company Overview
- 8.21.2 Key Products & Segments
- 8.21.3 Financial Performance (2023–2025)
- 8.21.4 Business Strategy
- 8.21.5 SWOT Analysis
- 8.21.6 Strategic Implications (2026–2032)
- 8.22 Lallemand Inc. (CA)
- 8.22.1 Company Overview
- 8.22.2 Key Products & Segments
- 8.22.3 Financial Performance (2023–2025)
- 8.22.4 Business Strategy
- 8.22.5 SWOT Analysis
- 8.22.6 Strategic Implications (2026–2032)
- 8.23 Zhejiang NHU Co., Ltd. (CN)
- 8.23.1 Company Overview
- 8.23.2 Key Products & Segments
- 8.23.3 Financial Performance (2023–2025)
- 8.23.4 Business Strategy
- 8.23.5 SWOT Analysis
- 8.23.6 Strategic Implications (2026–2032)
- 8.24 CSPC Pharmaceutical Group Limited (CN)
- 8.24.1 Company Overview
- 8.24.2 Key Products & Segments
- 8.24.3 Financial Performance (2023–2025)
- 8.24.4 Business Strategy
- 8.24.5 SWOT Analysis
- 8.24.6 Strategic Implications (2026–2032)
- 8.25 Northeast Pharmaceutical Group Co., Ltd. (CN)
- 8.25.1 Company Overview
- 8.25.2 Key Products & Segments
- 8.25.3 Financial Performance (2023–2025)
- 8.25.4 Business Strategy
- 8.25.5 SWOT Analysis
- 8.25.6 Strategic Implications (2026–2032)
- 8.26 Zhejiang Medicine Co., Ltd. (CN)
- 8.26.1 Company Overview
- 8.26.2 Key Products & Segments
- 8.26.3 Financial Performance (2023–2025)
- 8.26.4 Business Strategy
- 8.26.5 SWOT Analysis
- 8.26.6 Strategic Implications (2026–2032)
- 8.27 Roquette Frères (FR)
- 8.27.1 Company Overview
- 8.27.2 Key Products & Segments
- 8.27.3 Financial Performance (2023–2025)
- 8.27.4 Business Strategy
- 8.27.5 SWOT Analysis
- 8.27.6 Strategic Implications (2026–2032)
- 8.28 Tate & Lyle PLC (GB)
- 8.28.1 Company Overview
- 8.28.2 Key Products & Segments
- 8.28.3 Financial Performance (2023–2025)
- 8.28.4 Business Strategy
- 8.28.5 SWOT Analysis
- 8.28.6 Strategic Implications (2026–2032)
- 8.29 Hunan Green-Spring Biotechnology Co., Ltd. (CN)
- 8.29.1 Company Overview
- 8.29.2 Key Products & Segments
- 8.29.3 Financial Performance (2023–2025)
- 8.29.4 Business Strategy
- 8.29.5 SWOT Analysis
- 8.29.6 Strategic Implications (2026–2032)
- 8.30 Croda International Plc (GB)
- 8.30.1 Company Overview
- 8.30.2 Key Products & Segments
- 8.30.3 Financial Performance (2023–2025)
- 8.30.4 Business Strategy
- 8.30.5 SWOT Analysis
- 8.30.6 Strategic Implications (2026–2032)
- 8.31 EPAX AS (NO)
- 8.31.1 Company Overview
- 8.31.2 Key Products & Segments
- 8.31.3 Financial Performance (2023–2025)
- 8.31.4 Business Strategy
- 8.31.5 SWOT Analysis
- 8.31.6 Strategic Implications (2026–2032)
- 8.32 Bluestar Adisseo Company (CN)
- 8.32.1 Company Overview
- 8.32.2 Key Products & Segments
- 8.32.3 Financial Performance (2023–2025)
- 8.32.4 Business Strategy
- 8.32.5 SWOT Analysis
- 8.32.6 Strategic Implications (2026–2032)
- 8.33 Raisio plc (FI)
- 8.33.1 Company Overview
- 8.33.2 Key Products & Segments
- 8.33.3 Financial Performance (2023–2025)
- 8.33.4 Business Strategy
- 8.33.5 SWOT Analysis
- 8.33.6 Strategic Implications (2026–2032)
09Competitive Landscape
- 9.1 Competitive Landscape Overview
- 9.2 Competitive Intensity Assessment
- 9.3 Key Player Strategies & Positioning
- 9.4 Competitive Dynamics & Strategic Outlook
- 9.4.1 Emerging Competitive Threats
- 9.4.2 Consolidation vs. Fragmentation Outlook
- 9.4.3 Competitive Response Matrix
- 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
- 10.1 Threat of New Entrants
- 10.2 Bargaining Power of Buyers
- 10.3 Bargaining Power of Suppliers
- 10.4 Threat of Substitutes
- 10.5 Competitive Rivalry
11PESTLE Analysis
- 11.1 Political
- 11.2 Economic
- 11.3 Social and Demographic
- 11.4 Technological
- 11.5 Legal and Regulatory
- 11.6 Environmental
- 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
- 13.1 Future Trends & Outlook
- 13.1.1 Trend Summary and Commercial Maturity Assessment
- 13.1.2 Technology and Innovation Trends
- 13.1.3 Long-Term Market Outlook
- 13.1.4 Investment & M&A Activity Outlook
- 13.1.5 Overall Outlook Assessment
Frequently asked questions
How big is the global Immunity Support Ingredients market?
How fast is the Immunity Support Ingredients market expected to grow?
What does the Immunity Support Ingredients market cover?
What are the main segments of the Immunity Support Ingredients market by type?
Which applications drive demand in the Immunity Support Ingredients market?
Who are the key players in the Immunity Support Ingredients market?
Which regions and countries are covered for Immunity Support Ingredients?
What is driving growth in the Immunity Support Ingredients market?
Who should buy the Immunity Support Ingredients market report?
What license options are available for this report?
Research Methodology
All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.
Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.
Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.
Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.
CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.
All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.
On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.
Need a customized version?
Get country-, segment- or company-specific intelligence tailored to your exact requirements.
Request custom research →Request a free sample
Receive a sample of Global Immunity Support Ingredients Market Strategic Research Report before you buy.
Customize This Report
Describe your specific requirements and our analysts will scope and deliver a tailored version.
Request Invoice
We will email a proforma invoice within 24 hours. Report access is granted upon payment confirmation.
Navadhi Market Research · Pharmaceuticals